About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Georgia | 19,050 Studies Near You | Clareo Health

Clinical Trials LocationsGeorgia

Clinical Trials in Georgia

Discover 19,050 clinical trials near Georgia. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 15981-16000 of 19,050 trials

COMPLETEDNA63 miles

Aerobic Exercise to Improve Executive Language Function In Older Adults

NCT00979069

The purpose of this study is to see if exercise can improve brain function in older adults

US Department of Veterans Affairs20 participantsStarted Sep 2010

Gainesville, Florida, United States • Decatur, Georgia, United States

COMPLETEDPhase 365 miles

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia

NCT00731549

To evaluate the overall effectiveness of aripiprazole intramuscular (IM) depot as maintenance treatment in patients with schizophrenia.

Otsuka Pharmaceutical Development & Commercialization, Inc.1,081 participantsStarted Dec 2008

Chandler, Arizona, United States • Anaheim, California, United States • Cerritos, California, United States +211 more locations

Find Trials by Condition in Georgia

Breast Cancerin Georgia Lung Cancerin Georgia Prostate Cancerin Georgia Colorectal Cancerin Georgia Melanomain Georgia Leukemiain Georgia Lymphomain Georgia Pancreatic Cancerin Georgia Ovarian Cancerin Georgia Brain Cancerin Georgia Diabetes

Data from ClinicalTrials.govTerms

COMPLETEDPhase 365 miles

A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects

NCT00532779

The purpose of this study is to determine whether 2 doses of the combination of naltrexone SR and bupropion SR are safe and effective in the treatment of obesity.

ObesityOverweight

Orexigen Therapeutics, Inc1,742 participantsStarted Oct 2007

Birmingham, Alabama, United States • Fairhope, Alabama, United States • Chandler, Arizona, United States +31 more locations

COMPLETEDPhase 265 miles

A Multi-Center Study To Evaluate Multiple Doses of NT100 Following IVF In Women With Repeated IVF Failures (Thrive-IVF)

NCT01864356

The purpose of this study is to evaluate the efficacy, safety and tolerability of multiple doses of subcutaneous NT100 vs placebo following in vitro fertilization (IVF) in women with a history of repeated IVF failures.

Repeated IVF Failure

Nora Therapeutics, Inc.157 participantsStarted May 2013

Encino, California, United States • Newport Beach, California, United States • Pasadena, California, United States +18 more locations

COMPLETEDPhase 365 miles

Naturlose (D-Tagatose) Efficacy Evaluation Trial

NCT00955747

The purpose of this trial was to evaluate the effectiveness and safety of Naturlose (Tagatose) for glycemic control in people with Type 2 diabetes who were not taking other medications for the condition and who were under diet control and exercise. The study lasted approximately one year. HbA1c was monitored every 2 months after entry into the study. Safety and tolerance for tagatose were assessed every 2 months throughout the study. A total of 14 visits were made to the study site.

Type 2 Diabetes

Robert Lodder494 participantsStarted Apr 2007

Hueytown, Alabama, United States • Huntsville, Alabama, United States • Jonesboro, Arkansas, United States +43 more locations

TERMINATEDPhase 365 miles

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

NCT01650805

The purpose of this study is to compare the efficacy of ponatinib and imatinib in patients with newly diagnosed chronic myeloid leukemia (CML) in the chronic phase.

Chronic Myeloid Leukemia

Ariad Pharmaceuticals307 participantsStarted Jun 2012

Burbank, California, United States • Los Angeles, California, United States • Pleasant Hill, California, United States +167 more locations

COMPLETEDPhase 1/265 miles

Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma

NCT00024570

IL13-PE38QQR is an oncology drug product consisting of IL13 (interleukin-13) and PE38QQR (a bacteria toxin). IL3-PE38QQR is a protein that exhibits cell killing activity against a variety of IL13 receptor-positive tumor cell lines indicating that it may show a therapeutic benefit. In reciprocal competition experiments, the interaction between IL13-PE38QQR and the IL13 receptors was shown to be highly specific for human glioma cells. IL13-PE38QQR will be infused in two courses of 96 hours each, eight weeks apart, directly into the malignant brain tumors of patients to determine the dose of drug these patients can tolerate. After that, the selected dose will be studied to give an estimate of the response rate, response duration, time to response, and survival after infusing that dose of IL13-PE38QQR into the recurrent malignant glioma.

Malignant GliomaGlioblastoma MultiformeAnaplastic Astrocytoma+1 more

INSYS Therapeutics Inc60 participantsStarted Nov 2000

Birmingham, Alabama, United States • Tampa, Florida, United States • Atlanta, Georgia, United States +5 more locations

COMPLETEDPhase 372 miles

Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®

NCT01696058

The overall objective of this study is to assess efficacy and safety of 12 weeks, once daily, orally inhaled co-administration of olodaterol 5 µg (delivered by the Respimat® Inhaler) and tiotropium (delivered by the Handihaler® as Spiriva Handihaler®), compared to tiotropium (Spiriva Handihaler®) monotherapy on lung function in patients with COPD.

Pulmonary Disease, Chronic Obstructive

Boehringer Ingelheim1,137 participantsStarted Sep 2012

Anniston, Alabama, United States • Birmingham, Alabama, United States • Mobile, Alabama, United States +91 more locations

COMPLETEDPhase 478 miles

Avelox for Treatment of Elderly Patients With Community Acquired Pneumonia

NCT00665327

This study was to assess the safety of sequential intravenous (IV)/oral (PO) moxifloxacin (Avelox®) compared with sequential IV/PO levofloxacin (Levaquin®) in the treatment of elderly subjects (aged \≥ 65 years) with community-acquired pneumonia (CAP) who required initial IV therapy. This study also included an assessment of the clinical and bacteriologic effectiveness of both drugs.

Bayer401 participantsStarted Nov 2002

Mobile, Alabama, United States • Tucson, Arizona, United States • Tucson, Arizona, United States +74 more locations

COMPLETEDPhase 3144 miles

Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor

NCT00412061

The purpose of this study was to evaluate whether everolimus 10 mg / day added to treatment with depot octreotide prolongs progression free survival compared to treatment with octreotide alone in patients with advanced carcinoid tumor.

Carcinoid TumorMalignant Carcinoid Syndrome

Novartis Pharmaceuticals429 participantsStarted Dec 2006

Tucson, Arizona, United States • Fayetteville, Arkansas, United States • Little Rock, Arkansas, United States +67 more locations

COMPLETEDPhase 3164 miles

A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting

NCT01376297

NETU-10-29 is a clinical study assessing safety of netupitant and palonosetron, two antiemetic drugs, both given with oral dexamethasone. The objective of the study is to evaluate if netupitant and palonosetron are safe when administered to prevent nausea and vomiting after administration of repeated cycles of chemotherapy.

Chemotherapy-Induced Nausea and Vomiting

Helsinn Healthcare SA413 participantsStarted Jul 2011

Muscle Shoals, Alabama, United States • Burbank, California, United States • Los Angeles, California, United States +72 more locations

COMPLETED185 miles

DPBRN Reasons for Placing the First Restoration on Permanent Tooth Surfaces

NCT00847470

The purpose of this study was to document the reasons for placing the first restoration ("filling") on a previously un-restored surface in a permanent ("adult") tooth.

Dental Practice-Based Research Network5,810 participantsStarted Jun 2006

Birmingham, Alabama, United States • Gainesville, Florida, United States • Minneapolis, Minnesota, United States +4 more locations

COMPLETEDPhase 2250 miles

Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine

NCT01442675

The purpose of this trial is to describe the safety and antibody response to revaccination with Menactra vaccine in persons who received their first dose at ≥11 years of age. Primary Objective: \- To evaluate the antibody responses to meningococcal serogroups A, C, Y, and W-135, measured by serum bactericidal assay using human complement (SBA-HC), induced by Menactra vaccine in subjects who were first vaccinated with Menactra 4-6 years ago. Secondary Objective: \- To evaluate the antibody responses to serogroups A, C, Y, and W-135 in serum specimens collected 6 days post-vaccination in a subset of study population. Observational Objective: \- To describe the rates of immediate reactions, solicited injection-site and systemic reactions, unsolicited adverse events and serious adverse events following vaccination.

MeningitisMeningococcal Infection

Sanofi Pasteur, a Sanofi Company834 participantsStarted Sep 2011

Little Rock, Arkansas, United States • San Diego, California, United States • Bardstown, Kentucky, United States +12 more locations

COMPLETEDPhase 3339 miles

Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder

NCT01338818

This study will evaluate the long-term safety of methylphenidate hydrochloride extended release in adults with attention deficit/hyperactivity disorder

Attention Deficit/Hyperactivity Disorder

Novartis Pharmaceuticals299 participantsStarted Apr 2011

Little Rock, Arkansas, United States • Beverly Hills, California, United States • Spring Valley, California, United States +45 more locations

TERMINATEDPhase 2339 miles

Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer

NCT00549328

This study is designed to evaluate the efficacy and safety of monotherapy pazopanib (a small molecule tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGF, and c-kit) in subjects with advanced (Stage IIIB or IV) non-small cell lung cancer.

Lung Cancer, Non-Small Cell

GlaxoSmithKline14 participantsStarted Feb 2008

Scottsdale, Arizona, United States • Fort Myers, Florida, United States • Orlando, Florida, United States +10 more locations

COMPLETEDPhase 1/2359 miles

Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer

NCT01427946

Study IPI-504-15 is a Phase 1b/2 clinical trial to evaluate the safety and efficacy of retaspimycin HCl (IPI-504) plus everolimus in patients with KRAS mutant Non-small Cell Lung Cancer (NSCLC).

Non-small Cell Lung Cancer

Infinity Pharmaceuticals, Inc.47 participantsStarted Jul 2011

Aurora, Colorado, United States • Tampa, Florida, United States • Boston, Massachusetts, United States +2 more locations

COMPLETEDPhase 1583 miles

Encapsulated Calcium Absorption in Pregnancy

NCT01678079

This study will enroll at least 60 pregnant women in a randomized cross-over study in Dhaka, Bangladesh. Each participant will be randomized to one of 3 calcium doses: 500 mg, 1000 mg, 1500 mg elemental Ca per day. Each participant will undergo two calcium absorption tests, one with a micronutrient supplement powder containing non-encapsulated (non-coated) calcium and the other with a micronutrient supplement powder containing encapsulated calcium at the same dose. The absorption tests will be separated by a 2-week washout period. Fractional calcium absorption will be measured using the dual stable isotope method. For each test, the formulation will be administered orally for 9 days; on the 10th day, a 44Ca- labeled stable isotope will be given orally and a 42Ca-labeled stable isotope dose will be given intravenously. Urine will be collected for 48 hours to measure calcium absorption.

The Hospital for Sick Children61 participantsStarted Feb 2013

Baltimore, Maryland, United States • Houston, Texas, United States • Dhaka, Bangladesh +1 more locations

COMPLETEDPhase 4683 miles

Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control

NCT01438814

The aim of this study is to investigate the impact of the combination therapy of linagliptin and metformin at submaximal doses in reduction of Glycosylated haemoglobin (HbA1c) and metformin pre-specified gastro-intestinal (GI) side effects in treatment naive patients of with type 2 diabetes mellitus.

Diabetes Mellitus, Type 2

Boehringer Ingelheim689 participantsStarted Nov 2011

Dhaka, Bangladesh • Dhaka, Bangladesh • Dhaka, Bangladesh +87 more locations

TERMINATEDPhase 3726 miles

Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma

NCT00761280

In this multinational Phase III study the efficacy and safety of 10 µM AP 12009 is compared to standard chemotherapy (temozolomide or BCNU or CCNU) in adult patients with confirmed recurrent or refractory anaplastic astrocytoma (WHO grade III) or secondary glioblastoma (WHO grade IV).

Anaplastic AstrocytomaGlioblastoma

Isarna Therapeutics GmbH27 participantsStarted Dec 2008

Edison, New Jersey, United States • Mineola, New York, United States • Rochester, New York, United States +65 more locations

UNKNOWNPhase 2727 miles

Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Infection

NCT01872936

The purpose of this open-label study is to assess the safety, tolerability, antiviral activity, genotype resistance associated with virological failure, pharmacokinetics and pharmacodynamics of two dose regimens of miravirsen in combination with telaprevir and ribavirin in subjects with hepatitis C virus genotype 1 infection who are null responder to pegylated-interferon alpha and ribavirin.

Hepatitis C, Chronic

Santaris Pharma A/S20 participantsStarted Jun 2013

Dallas, Texas, United States • Houston, Texas, United States • San Juan, Puerto Rico

PreviousPage 800 of 953Next

in Georgia

Heart Diseasein Georgia